Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer. We enrolled women who had previously received first-line platinum-based therapy including bevacizomab. Median progression-free survival was 8.8 months.

Related Post